Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib

Paolo Grassi, Elena Verzoni, Luca Porcu, Roberto Iacovelli, Filippo De Braud, Giuseppe Procopio

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: This study investigated whether the effectiveness of first-line tyrosine-kinase inhibitors was associated with sites of disease in patients with metastatic renal cell carcinoma (mRCC). Methods: A retrospective cohort of consecutive mRCC patients receiving first-line sorafenib (SO) or sunitinib (SU) was analyzed. Results: In total, 203 patients received SO and 99 SU. In patients with liver metastasis, SU was associated with a 18% higher risk of time-to-treatment failure (TTF), and a 39% higher risk of death than SO: conversely, patients without liver metastases who received SU showed a 46% decreased risk of TTF and 62% decreased risk of death. Conclusions: mRCC patients with liver metastases treated with first-line SO showed a better outcome compared with SU, while mRCC patients without liver metastases treated with firstline SU showed a better outcome compared with SO.

Original languageEnglish
Pages (from-to)59-68
Number of pages10
JournalTherapeutic Advances in Urology
Volume7
Issue number2
DOIs
Publication statusPublished - Apr 27 2015

Fingerprint

Renal Cell Carcinoma
Neoplasm Metastasis
Liver
Treatment Failure
sorafenib
sunitinib
Protein-Tyrosine Kinases

Keywords

  • predictive factors
  • renal cell carcinoma
  • sites of metastases
  • sorafenib
  • sunitinib

ASJC Scopus subject areas

  • Urology

Cite this

@article{e9937509b0a240c38b231b9537956950,
title = "Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib",
abstract = "Background: This study investigated whether the effectiveness of first-line tyrosine-kinase inhibitors was associated with sites of disease in patients with metastatic renal cell carcinoma (mRCC). Methods: A retrospective cohort of consecutive mRCC patients receiving first-line sorafenib (SO) or sunitinib (SU) was analyzed. Results: In total, 203 patients received SO and 99 SU. In patients with liver metastasis, SU was associated with a 18{\%} higher risk of time-to-treatment failure (TTF), and a 39{\%} higher risk of death than SO: conversely, patients without liver metastases who received SU showed a 46{\%} decreased risk of TTF and 62{\%} decreased risk of death. Conclusions: mRCC patients with liver metastases treated with first-line SO showed a better outcome compared with SU, while mRCC patients without liver metastases treated with firstline SU showed a better outcome compared with SO.",
keywords = "predictive factors, renal cell carcinoma, sites of metastases, sorafenib, sunitinib",
author = "Paolo Grassi and Elena Verzoni and Luca Porcu and Roberto Iacovelli and {De Braud}, Filippo and Giuseppe Procopio",
year = "2015",
month = "4",
day = "27",
doi = "10.1177/1756287215571809",
language = "English",
volume = "7",
pages = "59--68",
journal = "Therapeutic Advances in Urology",
issn = "1756-2872",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib

AU - Grassi, Paolo

AU - Verzoni, Elena

AU - Porcu, Luca

AU - Iacovelli, Roberto

AU - De Braud, Filippo

AU - Procopio, Giuseppe

PY - 2015/4/27

Y1 - 2015/4/27

N2 - Background: This study investigated whether the effectiveness of first-line tyrosine-kinase inhibitors was associated with sites of disease in patients with metastatic renal cell carcinoma (mRCC). Methods: A retrospective cohort of consecutive mRCC patients receiving first-line sorafenib (SO) or sunitinib (SU) was analyzed. Results: In total, 203 patients received SO and 99 SU. In patients with liver metastasis, SU was associated with a 18% higher risk of time-to-treatment failure (TTF), and a 39% higher risk of death than SO: conversely, patients without liver metastases who received SU showed a 46% decreased risk of TTF and 62% decreased risk of death. Conclusions: mRCC patients with liver metastases treated with first-line SO showed a better outcome compared with SU, while mRCC patients without liver metastases treated with firstline SU showed a better outcome compared with SO.

AB - Background: This study investigated whether the effectiveness of first-line tyrosine-kinase inhibitors was associated with sites of disease in patients with metastatic renal cell carcinoma (mRCC). Methods: A retrospective cohort of consecutive mRCC patients receiving first-line sorafenib (SO) or sunitinib (SU) was analyzed. Results: In total, 203 patients received SO and 99 SU. In patients with liver metastasis, SU was associated with a 18% higher risk of time-to-treatment failure (TTF), and a 39% higher risk of death than SO: conversely, patients without liver metastases who received SU showed a 46% decreased risk of TTF and 62% decreased risk of death. Conclusions: mRCC patients with liver metastases treated with first-line SO showed a better outcome compared with SU, while mRCC patients without liver metastases treated with firstline SU showed a better outcome compared with SO.

KW - predictive factors

KW - renal cell carcinoma

KW - sites of metastases

KW - sorafenib

KW - sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84925597560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925597560&partnerID=8YFLogxK

U2 - 10.1177/1756287215571809

DO - 10.1177/1756287215571809

M3 - Article

VL - 7

SP - 59

EP - 68

JO - Therapeutic Advances in Urology

JF - Therapeutic Advances in Urology

SN - 1756-2872

IS - 2

ER -